East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dapagliflozin Tablets, 5 mg and 10 mg. Aurobindo Pharma’s Dapagliflozin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Farxiga Tablets, manufactured by AstraZeneca AB.

Dapagliflozin Tablets are indicated as:

• An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.